Friday, September 22, 2023
Friday, September 22, 2023

MR Solutions Now Offers the Widest Range of Preclinical Nuclear Medicine Imaging Systems of Any Manufacturer

A world leader in helium free MRI systems for preclinical research laboratories MR Solutions has now developed the largest and most advanced range of preclinical nuclear medicine combination systems of any manufacturer.

The PET and SPECT nuclear systems can be stand-alone or clipped onto the front of any of MR Solutions’ extensive range of high field, liquid helium free MRI systems or its range of cutting edge CT systems. The PET scanners can also be configured to operate as an insert in the bore of all the MRI systems providing simultaneous imaging. The PET and SPECT scanners range in size from 15 g for small rodents up to 12 kgs for larger animals.

The PET insert (for simultaneous scanning) or PET clip-on module (for sequential scanning) use the latest silicon photomultiplier (SiPM) technology. This provides true depth of interaction (DOI) from hardware with two pixelated layers of scintillator crystal with different matrices providing <0.8 mm resolution. All of the PET modules are fitted with MR Solution’s superior ringless detector technology.

The SPECT clip-on modules are available in different configurations with a range of transaxial views allowing optimal imaging for different sized animals.

All of MR Solution’s preclinical scanning systems are fitted with the easy to use Preclinical Scan multimodality interface. This software provides access to all the functions – MRI/CT/PET/SPECT.  Advanced functionalities are available for experienced users.

Both the CT and MRI scanners include a motorized animal bed allowing the animal to be scanned without any manual input from the operator. These precision animal beds are compatible across all of MR Solutions’ CT and MRI ranges.

MR Solutions, based in the UK, has over 30 years’ experience and in excess of 2000 installations including spectrometer sales across the world. MR Solutions holds the prestigious Queen’s Award for Enterprise awards, achieving this for Innovation in 2016 and 2019 and for International Trade in 2017. MR Solutions also has offices in the US and technical support in all the major centers.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase...

The EV-302 study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), compared to chemotherapy. An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis. The safety results of the combination are consistent with those of enfortumab vedotin in combination with pembrolizumab previously reported in cisplatin-ineligible patients with la/mUC.

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

"Dosing the first patient, on time, is a testament to our commitment to the clinical development of DA-1241 in patients with NASH," stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. "Based on the pre-clinical and clinical evidence generated to date, DA-1241 has demonstrated reduced hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control, and was shown to be well tolerated in both healthy volunteers and in patients with type 2 diabetes mellitus (T2DM). Given this data, we believe that the mechanism of action of this promising cardiometabolic asset will translate into a safe and effective treatment for NASH, a disease with no current treatment options. The two-part design of this trial provides optionality for a potential interim analysis in the first half of 2024 and we expect to report the full data in the second half of 2024."

Medmain Inc. Has Been Selected for the U.S. Market Gateway Accelerator for BioSciences and MedTech

The "U.S. Market Gateway Accelerator for BioSciences and MedTech", sponsored by WorldUpstart, LLC, is an acceleration program that provides medical tech and life sciences startups with a proven track record outside the U.S. with the opportunity to enter and grow their business in the U.S. market.

Karger Publishers New Journal – Immune System

“Immune System is an innovative Open Access journal, welcoming articles with a broad background from basic science to clinical research, as long as the manuscript focuses on certain aspects of our immune response,” states editor-in-chief Désirée Larenas-Linnemann."

MindMed Completes Enrollment of Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)

Robert Barrow, Chief Executive Officer and Director of MindMed. “Thanks in large part to the enthusiasm we have seen regarding MM-120 among investigators and patients, as well as the strong execution of our team, we were able to enroll almost 200 participants in this trial in just over a year. We anticipate sharing topline results during the fourth quarter of this year.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy